Discover

SBFM
Sunshine Biopharma, Inc.
1.23
1 x 1.17
10 x 1.35
bid
ask
-
0.17
12.14%
270 @ 04:00 PM
1.26 +0.03 (2.45%)
Ytd-90.00%
1y-91.21%
1.12
day range
1.50
1.10
52 week range
24.30
Open1.50Prev Close1.40Low1.12High1.50Mkt Cap2.93M
Vol11.23MAvg Vol1.89MEPS-6.08P/E-0.20Forward P/E0.02
Beta-1.04Short Ratio0.39Inst. Own1.84%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1850-d Avg1.98200-d Avg9.661yr Est300.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-052024-090-0.94N/AN/A
2024-08-162024-060-9.94N/AN/A
2024-05-202024-030-40N/AN/A
2024-03-282023-120-100N/AN/A
2023-11-132023-090-80N/AN/A
2023-08-112023-060-40N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-12-05Aegis CapitalUpgradeBuyBuy
2023-08-07Aegis CapitalUpgradeBuy
Profile
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
Insider Holder
DateNameRelationQuantityDescription
2021-01-05MERZOUKI ABDERRAZZAKChief Operating Officer23.34MStock Award(Grant)
2022-11-29SEBAALY CAMILLEChief Financial Officer174.47KPurchase
2021-01-05SLILATY STEVE NChief Executive Officer23.34MStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Bank of America Corporation34.48K103.44K1.72%
2024-09-29Nordwand Advisors, LLC 500.001.50K0.03%
2024-09-29Rise Advisors, LLC 1.003.000.00%
2024-09-29Farther Finance Advisors, Llc1.003.000.00%
2024-09-29National Bank of Canada/FI7.0021.000.00%
2024-09-29Federation Des Caisses Desjardins Du Quebec1.003.000.00%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-08-30Fidelity NASDAQ Composite Index Fund11.0033.000.00%
Split
SplitDate
1 : 102026-06-01
1 : 202024-08-08
1 : 1002024-04-17
1 : 2002022-02-09
1 : 202020-04-06
1 : 202019-02-01